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Objectives The aim of this prospective, randomized study was to evaluate the effects of telmisar-
tan, compared with the calcium-channel blocker amlodipine, on endothelial function after coronary
drug-eluting stent (DES) implantation in hypertensive patients.
Background DES implantation impairs local endothelial function, which may be associated with fu-
ture cardiovascular events. Telmisartan, which has unique peroxisome proliferator-activated-receptor-
gamma–mediated effects in addition to its renin-angiotensin system–inhibition effects, has favorable
effects on endothelial function.
Methods Fifty-one hypertensive patients with coronary artery stenosis but without coronary artery
spasm, treated with a sirolimus-eluting stent, were randomly assigned to either the telmisartan (25
cases) or amlodipine (26 cases) treatment groups. At baseline and at 3 months after DES implanta-
tion, endothelium-dependent and -independent vasomotion were evaluated by quantitative coro-
nary angiography under the condition of medication withdrawal. The mean luminal diameter of a
20-mm coronary segment, beginning 5 mm distal to the stent, was measured before and after infu-
sion of intracoronary acetylcholine (107, 106 mol/l) and then again after infusion of nitroglycerin.
Results Blood pressure was comparable between groups at baseline and after 3 months. Vasocon-
striction after acetylcholine infusion at 3 months (impaired endothelial function) was less pro-
nounced in the telmisartan group than in the amlodipine group (p  0.0001), although there was
no signiﬁcant difference between the 2 groups before DES implantation. The response to nitroglyc-
erin did not differ between groups before or at 3 months after DES implantation.
Conclusions Telmisartan, compared with amlodipine, signiﬁcantly ameliorated endothelial dys-
function after DES implantation in terms of vasoconstriction induced by acetylcholine. (J Am
Coll Cardiol Intv 2012;5:182–90) © 2012 by the American College of Cardiology Foundation
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183Drug-eluting stents (DES) are widely used for the treat-
ment of coronary artery disease to reduce both the rate of
restenosis and the subsequent need for target lesion reinter-
vention. Endothelial dysfunction after DES implantation is
a concern (1–5), however, and might contribute to the
development of severe adverse cardiac events. Therefore,
amelioration of endothelial dysfunction after DES implan-
tation might improve prognosis.
Angiotensin-converting enzyme inhibitors and angiotensin-II
receptor blockers (ARB), which block the renin-angiotensin
system, are widely used for their organoprotective actions, as
well as for the treatment of hypertension (6). Among
various organoprotective actions, renin-angiotensin system
blockers favorably affect endothelial function (7–9). Telmis-
artan, an ARB, has unique peroxisome proliferator-
activated receptor (PPAR)-gamma–mediated effects in ad-
dition to ARB class effects and is expected to improve
endothelial function through several mechanisms, including
angiotensin II inhibition with type-1 receptor blockade and
induction of adiponectin via PPAR-gamma–mediated ef-
fects (10–12).
This prospective, randomized study compared the effects of
telmisartan to a calcium-channel blocker, amlodipine, on
endothelial function after DES implantation in hypertensive
patients.
Methods
Study patients. Patients between 20 and 80 years of age with
linically stable angina pectoris and hypertension scheduled for
ercutaneous coronary intervention (PCI) were enrolled.
nclusion criteria were: 1) hypertension defined based on
he criteria put forth in the guidelines of the Japanese
ociety of Hypertension or use of an antihypertensive
rug; 2) stable angina pectoris with a single de novo stenotic
esion (75% to 90% diameter stenosis) in the native coronary
rtery with a lesion length eligible for treatment with 1 or 2
irolimus-eluting stents (SES) (Cypher, Cordis Corp., Mi-
mi Lakes, Florida) and with a reference vessel diameter of
t least 2.5 mm and 4.0 mm. Exclusion criteria were:
) vasospastic angina pectoris; 2) unstable angina pectoris or
yocardial infarction within 4 weeks; 3) left main coronary
rtery disease; 4) totally or subtotally occluded lesion;
) bifurcation lesion treated with bifurcation stenting; 6)
ypass graft lesion; 7) previous PCI for the target vessel;
) cardiogenic shock; 9) left ventricular ejection fraction
30%; 10) serum creatinine levels 1.5 mg/dl; and 11)
udged by the investigator to be inappropriate for participa-
ion in this study. The study protocol was approved by the
nstitutional review board, and all patients provided written
nformed consent.
Evaluation of endothelial function. Coronary angiography
CAG) to evaluate endothelial function was performed both
t the pre-intervention state and at the 3-month follow-up.edications with potential effects on vasomotor responses
ere withheld for at least 48 h before CAG, except for
ublingual nitroglycerin (NTG) as needed. CAG was per-
ormed after injection of 2,000 U of heparin, and all drugs
ere infused through the catheter selectively engaged in the
arget vessel. To evaluate endothelial function, endothelium-
ependent and -independent vasomotor responses to intra-
oronary infusion of increasing doses of acetylcholine (ACh)
r nitrates were assessed. As baseline, physiological saline
as infused for 2 min at an infusion rate of 2 ml/min,
ollowed by baseline CAG. Thereafter, the endothelium-
ependent vasomotor response was evaluated over a 2-min
nfusion of ACh in increasing doses (1.4 and 14 g/min;
estimated 107 and 106 mol/l) into the target vessel with
5-min interval between doses. A temporary pacemaker was
inserted if clinically needed. Subsequently, an intracoronary
bolus injection of NTG (200
g) was administered to assess
the endothelium-independent
vasomotor response. CAG was
repeated after each dose of ACh
and within 2 min of NTG admin-
istration. Patient’s symptoms, blood
pressure, heart rate, and 12-lead
electrocardiogram were continu-
ously monitored during the study.
Assessment of coronary artery
diameter in response to ACh
or NTG infusion. During the
evaluation of endothelial func-
tion, projection of the CAG was
fixed at the most suitable posi-
tion with little foreshortening
and without overlapping of side
branches. At the follow-up
study, care was taken to replicate
angiographic views, tube height,
and catheter positions used in
the baseline study. Thus, the same conditions for assessment
of the coronary artery were prepared for both the pre-
intervention and follow-up studies. Offline quantitative
CAG was performed using the subsegmental analysis
method with an automated edge detection program (Car-
diovascular Measurement System Medical Imaging System,
Leiden, the Netherlands). The mean luminal diameter of a
20-mm coronary segment, beginning 5 mm distal to the
stent and ending 25 mm distal to the stent (Fig. 1), was
measured at baseline, after intracoronary infusion of ACh,
and after intracoronary infusion of NTG. To evaluate
vasomotor responses at the pre-intervention state, the mean
luminal diameter of the corresponding 20-mm segment,
identified in reference to specific anatomic landmarks on
CAG before and after SES implantation, was measured in
Abbreviations
and Acronyms
ACh  acetylcholine
ARB  angiotensin-II
receptor blocker(s)
CAG  coronary angiography
DES  drug-eluting stent(s)
LDL  low-density
lipoprotein
NAD(P)H  reduced
nicotinamide adenine
dinucleotide phosphate
NO  nitric oxide
NTG  nitroglycerin
PCI  percutaneous
coronary intervention
PPAR  peroxisome
proliferator-activated
receptor
SES  sirolimus-eluting
stent(s)the same manner. Changes in coronary diameter in response
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184to intracoronary infusion of ACh and NTG were expressed
as percentage changes versus control angiograms (angio-
grams after saline infusion). Measurements were performed
by 2 independent reviewers blinded to the patients’
information.
Interobserver and intraobserver variability for quantitative
CAG measurements were assessed in 10 randomly selected
patients after intracoronary infusion of saline, 107 mol/l
Ch, 106 mol/l ACh, and NTG.
Treatment and follow-up. After evaluation of endothelial
function at the pre-intervention state, all patients under-
went SES implantation using standard techniques. Stents
were implanted after a pre-dilation procedure, and the
pre-dilation site and atherosclerotic lesions were fully cov-
ered with 1 or 2 SES. All patients received oral aspirin (100
mg/day) and clopidogrel 75 mg for at least 2 days before
PCI and continued during the follow-up period.
As described previously, before PCI, all medications with
potential effects on vasomotor responses, including any
antihypertensive drugs, were withheld for at least 48 h
before CAG, and then patients were randomly assigned to
the telmisartan treatment group or the amlodipine treat-
Figure 1. Measurement of the Mean Luminal Diameter
The mean luminal diameter of a 20-mm coronary segment, beginning
5 mm distal to the stent and ending 25 mm distal to the stent, was
measured after intracoronary infusion of saline, 107 mol/l acetylcholine,
106 mol/l acetylcholine, and nitroglycerin, respectively, using the subseg-
mental analysis method with an automated edge detection program.
SES  sirolimus-eluting stent(s).ment group. Each drug was administered after SES implan-tation and titrated to the maximally tolerated dose (telmis-
artan: 40 to 80 mg, amlodipine: 5 to 10 mg) during the
follow-up periods. If the blood pressure–reducing effect was
not adequate, despite a maximum dose, patients were
treated with a combination of diuretics, alpha-blockers,
and/or beta-blockers per physician’s guidance. In addition,
fluvastatin 30 mg was administered in all patients, regardless
of the serum low-density lipoprotein (LDL) level, and
thiazolidinedione was not administered to any patients after
SES implantation.
Laboratory tests. Laboratory tests, including lipid profiles
total, LDL, and high-density lipoprotein cholesterol and
riglyceride), diabetic parameters (fasting blood sugar and
emoglobin A1c), high-sensitivity C-reactive protein, and adi-
ponectin were performed at the pre-intervention state and at
the 3-month follow-up.
Statistical analysis. We determined sample size based on a
previous randomized study comparing telmisartan and amlo-
dipine based on peripheral vascular endothelial function (flow-
mediated dilation) in patients with essential hypertension (13).
Statistical analysis was performed with StatView version 5.0
(SAS Institute, Cary, North Carolina). For continuous vari-
ables, differences between groups were evaluated using the
unpaired t test or Mann-Whitney rank-sum test, and those
within groups were evaluated using paired t test or Wilcoxon
signed rank test. Change in coronary lumen diameters in
response to infusion of 107 and 106 mol/l ACh were
ompared between groups and between the values before
ntervention and 3 months after SES implantation using a
epeated measured analysis of variance. For discrete variables,
ifferences were expressed as counts and percentages and
nalyzed with a chi-square (or Fisher exact) test between
roups and with a McNemar test or Fisher exact test within
roups, as appropriate. A 2-tailed p value of 0.05 was
considered statistically significant. Data are expressed as
mean  SD. When the variable was significantly skewed,
the median (25th to 75th percentiles) was reported.
Results
Between July 2008 and June 2009, 51 patients, who were
eligible based on the inclusion criteria, were enrolled in this
study, and 25 patients were assigned to the telmisartan
treatment group and 26 were assigned to the amlodipine
treatment group (Fig. 2). At the before-intervention evalu-
ation of endothelial function, 4 patients in the telmisartan
group and 5 patients in the amlodipine group were excluded
because they demonstrated a coronary spasm with total or
subtotal occlusion (90% stenosis) at the target lesion for
SES implantation or had more than 50% coronary vasocon-
striction at other sites in response to ACh infusion. SES
were successfully implanted in all patients under intravas-
cular ultrasound guidance. Twenty-one patients in each
group underwent a 3-month follow-up CAG. None of
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185them demonstrated angiographic restenosis, and endothelial
function was evaluated.
Patient characteristics and serial changes in blood pressure
and in laboratory data. Patient characteristics at baseline are
ummarized in Table 1. There were no significant differ-
nces in baseline patient characteristics between groups. At
he time of enrollment, 17 (81.0%) and 19 (90.5%) patients
ere being treated with antihypertensive agents, including
ngiotensin-converting enzyme inhibitors, ARB, calcium
hannel blockers, and beta-blockers, which did not differ
ignificantly between groups. At baseline, 10 patients
47.6%) in the telmisartan treatment group and 7 (33.3%) in
he amlodipine treatment group were receiving statins (p 
.34), which were replaced with fluvastatin 30 mg. Oral
lycemic agents for diabetes mellitus were being taken by 6
atients (28.6%) in the telmisartan treatment group and 3
14.3%) in the amlodipine group (p  0.26), and none of
he patients required insulin treatment. Pioglitazone was
dministered to 1 patient in each group and was withheld
or 48 h before PCI and discontinued during the follow-up
eriod. Angiographic and procedural characteristics of PCI
ere not significantly different between groups (Table 1).
The applied doses of telmisartan or amlodipine and
djuvant remedies during follow-up periods are presented in
able 2. None of the patients quit taking telmisartan or
mlodipine. Systolic, diastolic, and mean blood pressure at
aseline, after 3 months, and changes during the 3 months
as comparable between groups, although blood pressure
ignificantly improved in both groups (Table 3).
Serial changes in laboratory tests are presented in Table 4.
Figure 2. Study Flow
CAG  coronary angiography; pts  patients; SES  sirolimus-eluting
stent(s).here were no significant differences between groups in theaseline values of the lipid profiles, diabetic parameters
fasting blood sugar and hemoglobin A1c) and high-sensitivity
-reactive protein and those at the 3-month follow-up, or in
he changes in these parameters from the baseline state to the
-month follow-up, except for LDL cholesterol and adiponec-
in. After 3 months, LDL cholesterol significantly decreased in
he telmisartan group (p  0.021), but not in the amlodipine
roup. From baseline to the 3-month follow-up, there was a
onsignificant trend toward a reduction in adiponectin levels in
he amlodipine group (p  0.067), and the change from the
Table 1. Baseline Patient, Angiographic, and Procedural Characteristics
Telmisartan
(n  21)
Amlodipine
(n  21) p Value
Age, yrs 67.9 8.9 66.6 8.7 0.62
Male 17 (81.0) 18 (85.7) 0.68
Body mass index, kg/m2 23.8 3.5 24.5 3.3 0.52
Diabetes mellitus 7 (33.3) 3 (14.3) 0.15
Dyslipidemia 12 (57.1) 9 (42.9) 0.35
Current smoker 5 (23.8) 5 (23.8) 0.99
Prior myocardial infarction 7 (33.3) 3 (14.3) 0.15
Prior PCI 10 (47.6) 5 (23.8) 0.10
Treated vessels
LAD/LCx/RCA 11/6/4 9/6/6 0.74
AHA/ACC type B2/C 18 (85.7) 16 (76.2) 0.43
Lesion length, mm 16.4 8.8 16.2 6.8 0.55
Reference vessel diameter, mm 2.63 0.33 2.81 0.38 0.10
%diameter stenosis, pre-intervention 61.1 8.6 63.2 10.0 0.46
%diameter stenosis, post-intervention 8.7 7.8 6.6 6.2 0.34
Number of stents, 1 stent/2 stents 18/3 19/2 0.99
Stent diameter, mm 3.0 0.4 3.0 0.4 0.99
Stent length, mm 22.5 11.0 20.5 8.6 0.52
Final balloon pressure, atm 17.6 3.2 18.9 3.0 0.17
Values are mean SD or n (%).
ACCAmericanCollegeof Cardiology; AHAAmericanHeart Association; LAD left anterior
descending coronary artery; LCx left circumflex coronary artery; PCI percutaneous coronary
intervention; RCA right coronary artery.
Table 2. Medication During Follow-Up Periods
Telmisartan
(n  21)
Amlodipine
(n  21) p Value
Telmisartan, mg 78.1 8.8 — NA
Amlodipine, mg — 7.9 2.5 NA
Beta-blockers 0 (0) 2 (9.5) 0.15
Alpha-blockers 2 (9.5) 5 (23.8) 0.21
Diuretics 4 (19.0) 6 (28.6) 0.47
Oral glycemic agents 7 (33.3) 3 (14.3) 0.14
Pioglitazone 0 (0) 0 (0) 0.99
Insulin 0 (0) 0 (0) 0.99
Aspirin 21 (100) 21 (100) 0.99
Clopidogrel 21 (100) 21 (100) 0.99
Cilostazol 1 (4.8) 0 (0) 0.31
Values are mean SD or n (%).NA not applicable.
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186baseline value to follow-up was significantly different between
treatment groups.
Vasomotion in response to intracoronary infusion of ACh or
NTG. Absolute values in the mean lumen diameters in
esponse to intracoronary infusion of ACh and NTG are
hown in Table 5. Before SES implantation, there was no
ignificant difference between groups in terms of the mean
umen diameter in response to the infusion of saline
control), 107 mol/l ACh infusion, 106 mol/l ACh
nfusion, and NTG infusion. At the 3-month follow-up,
here were no differences between groups in the lumen size
n response to saline or NTG infusion; however, the mean
umen diameters in response to 107 mol/l ACh and 106
mol/l ACh infusion were significantly smaller in the amlo-
dipine group than in the telmisartan group.
Percentage of change in the mean lumen diameter for the
evaluation of vasomotion in response to intracoronary infu-
sion of ACh and NTG is shown in Figure 3. Before SES
implantation, mild but significant vasoconstriction was ob-
served in response to ACh infusion in both groups (p 
0.0001), but there was no significant difference between
groups in the vasoconstriction induced (p  0.81). At the
-month follow-up, however, vasoconstriction was signifi-
antly greater in the amlodipine group than in the telmis-
rtan group (p  0.0001). In an additional analysis of
ovariance analysis, including LDL reduction as covariate,
he results were unchanged. Endothelial dysfunction was
ot correlated with drug dose or blood pressure change.
In the amlodipine group, the magnitude of vasoconstric-
ion in response to infusion of 107 and 106 mol/l ACh
as greater at the 3-month follow-up than in the pre-SES
mplantation state (16.0  21.2% and 35.5  27.8% vs.
1.8 1.5% and5.7 6.8%, p 0.005 and p 0.0001,
respectively). In the telmisartan group, however, greater
Table 3. Serial Changes in Blood Pressure
Telmisartan
(n  21)
Amlodipine
(n  21) p Value
Baseline
Systolic BP, mm Hg 141 24 143 14 0.72
Diastolic BP, mm Hg 73 9 78 11 0.12
Mean BP, mm Hg 119 18 122 11 0.50
3-month follow-up
Systolic BP, mm Hg 129 16 132 14 0.46
Diastolic BP, mm Hg 76 14 78 9 0.57
Mean BP, mm Hg 111 15 114 11 0.45
Change of BP during follow-up
Systolic BP, mm Hg 13 15 11 18 0.80
Diastolic BP, mm Hg 3 12 0 14 0.47
Mean BP, mm Hg 7 10 8 14 0.98
Values are mean SD.
BP blood pressure.vasoconstriction was observed only after the infusion of106 mol/l ACh at the 3-month follow-up compared with
that before SES implantation (8.7  5.6% vs. 6.3 
3.6%, p  0.048).
There was no significant difference between treatment
groups in vasodilatation by NTG before SES implantation
or at the 3-month follow-up.
Representative cases of each group are shown in Figures 4
and 5.
Interobserver and intraobserver variability. Inter- and in-
raobserver variability for quantitative CAG measurements
ere 0.05  0.03 mm and 0.01  0.02 mm.
iscussion
The findings of the present study demonstrated that, compared
with a calcium-channel blocker, amlodipine, treatment, telmis-
artan treatment for hypertensive patients after SES implanta-
tion significantly ameliorated endothelial dysfunction in terms
of vasoconstriction induced by infusion of ACh although there
Table 4. Serial Changes in Laboratory Data
Telmisartan
(n  21)
Amlodipine
(n  21)
p
Value
LDL cholesterol, mg/dl
Baseline 113 27 104 30 0.33
3-month follow-up 101 28 111 27 0.25
∆ (follow-up – baseline) 11 21 7 22 0.01
HDL cholesterol, mg/dl
Baseline 48 12 51 13 0.50
3-month follow-up 48 12 53 12 0.14
∆ (follow-up – baseline) 0 8 3 9 0.25
Triglyceride, mg/dl
Baseline 146 81 140 79 0.80
3-month follow-up 137 76 122 58 0.49
∆ (follow-up – baseline) 9 67 17 69 0.70
FBS, mg/dl
Baseline 130 45 113 20 0.10
3-month follow-up 131 63 111 15 0.15
∆ (follow-up – baseline) 1 43 2 15 0.74
Hemoglobin A1c, %
Baseline 6.1 1.3 5.7 0.6 0.21
3-month follow-up 6.1 1.2 6.0 0.9 0.79
∆ (follow-up – baseline) 0.1 0.4 0.2 0.4 0.10
hs-CRP, mg/dl
Baseline 0.52 (0.32 to 1.26) 0.51 (0.19 to 0.71) 0.42
3-month follow-up 0.40 (0.21 to 0.77) 0.70 (0.26 to 1.29) 0.06
∆ (follow-up – baseline) 0.28 (0.42 to0.05) 0.01 (0.05 to0.48) 0.13
Adiponectin, mg/dl
Baseline 8.1 4.9 11.1 4.7 0.16
3-month follow-up 8.4 4.4 9.5 3.7 0.62
∆ (follow-up – baseline) 0.4 1.0 1.6 2.4 0.02
Values are mean SD or median (interquartile range).
FBS  fasting blood sugar; HDL  high-density lipoprotein; hs-CRP  high-sensitivityC-reactive protein; LDL low-density lipoprotein.
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187was no significant difference between groups in endothelium-
independent vasodilation by NTG. Furthermore, telmisartan
treatment reduced LDL cholesterol and preserved plasma
adiponectin concentrations.
Endothelial dysfunction after DES implantation. In patients
ith coronary artery disease, DES dramatically reduces
estenosis as a major problem after bare-metal stent implan-
ation. Endothelial dysfunction after DES implantation has
ecently become a concern (1–3), and several case reports
ndicate that severe coronary spasm after DES implantation
as probably associated with endothelial dysfunction, lead-
ng to serious cardiac events, such as myocardial infarction,
atal arrhythmia, or sudden cardiac death (4). Endothelial
ysfunction after DES implantation may also contribute to
ate stent thrombosis, a life-threatening complication
5,14). Thus, coronary endothelial dysfunction might have a
rucial role in the long-term cardiovascular prognosis for
atients treated with DES, as in patients with established
therosclerosis or early disease (15).
Table 5. Serial Changes in Mean Lumen Diameters in Response to
ACh and NTG Infusion
Telmisartan
(n  21)
Amlodipine
(n  21) p Value
Before SES implantation, mm
Control 1.98 0.43 1.89 0.23 0.39
ACh 107 mol/l 1.92 0.42 1.85 0.24 0.50
ACh 106 mol/l 1.85 0.42 1.78 0.30 0.55
NTG 2.14 0.45 2.06 0.28 0.46
3-month follow-up, mm
Control 1.94 0.44 1.81 0.24 0.24
ACh 107 mol/l 1.87 0.45 1.53 0.44 0.02
ACh 106 mol/l 1.78 0.44 1.18 0.55 0.003
NTG 2.16 0.46 2.08 0.25 0.48
Values are mean SD.
ACh acetylcholine; NTG nitroglycerin; SES sirolimus-eluting stent(s).
Figure 3. Percentage of Change in the Mean Luminal Diameter After Intrac
Changes in coronary vessel diameter in response to intracoronary infusion of a
versus control angiograms (angiograms after saline infusion). Endothelial funct
PCI  percutaneous coronary intervention.Potential mechanisms of endothelial dysfunction specific
o DES implantation include delayed endothelial repair by
he original action of the DES drug (neointimal inhibition)
nd direct negative actions of the drug. Pathological data
ndicate delayed endothelial repair (16,17), and this physical
elay would result in a functional delay, namely, insufficient
itric oxide (NO) production, which is thought to contrib-
te to endothelial dysfunction caused by DES. Obata et al.
18) and Guba et al. (19) reported that sirolimus reduces the
roduction of vascular endothelial growth factor and atten-
ates the response of the vascular endothelium to vascular
ndothelial growth factor, causing delayed endothelial repair
fter vascular injury.
DES drugs also have direct negative actions. In vitro, Jabs et
l. (20) showed that sirolimus induces endothelial dysfunction
ia increased mitochondrial and reduced nicotinamide adenine
inucleotide phosphate (NAD(P)H) oxidase-dependent su-
eroxide production and decreases vascular NO formation.
Endothelial dysfunction is associated with a worse clinical
utcome in patients with established atherosclerosis or early
isease (15). Interventions to reverse endothelial dysfunction
mprove clinical outcome (21). Although the exact mecha-
isms of endothelial dysfunction after DES implantation
emain unknown, reversal of endothelial dysfunction might
mprove the long-term outcome in patients treated with DES.
Effects of an ARB on endothelial dysfunction. The renin-
ngiotensin system contributes to endothelial injury by the
ollowing mechanisms. Angiotensin II increases NAD(P)H
xidase activity (22), leading to increased production of reactive
xygen species and NO inactivation. Furthermore, the balance
etween angiotensin II and NO is a major determinant of
ndothelial and vascular phenotype (23). Therefore,
ngiotensin-II inhibition by an angiotensin-II type-1 receptor
lockade would reverse endothelial dysfunction (24). Several
tudies have demonstrated that inhibition of the vascular
ngiotensin-II type-1 receptors in patients with atherosclerosis
ry Infusion of ACh and NTG
holine (ACh) and nitroglycerin (NTG) are expressed as percentage of change
as evaluated at the pre-intervention state and at the 3-month follow-up.orona
cetylc
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188improves coronary and peripheral vasomotion (7–9). Angio-
tensin receptor blockers also appear to reduce endothelial
markers of inflammation and oxidative stress (25).
Figure 4. Representative Case of the Amlodipine Treatment Group
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189combination of candesartan and pioglitazone (a PPAR-
gamma agonist) more effectively restored endothelial func-
tion after SES implantation than candesartan monotherapy
did (27). Because PPAR-gamma activation inhibits the
expression of inflammatory genes, the effect on endothelial
function could potentially be mediated by an improvement
in inflammation (28). Moreover, the inhibitory effects of
sirolimus on circulating endothelial progenitor cells would
be associated with delayed reendothelialization after SES
implantation. The benefits of PPAR-gamma agonists on
the endothelial progenitor cell endothelialization capacity
would improve endothelial dysfunction (29).
Telmisartan induces adiponectin protein expression in
adipocytes at a post-transcriptional level via its PPAR-
gamma–activating effect, leading to an increase in adiponec-
tin plasma levels (30). Adiponectin is an adipocyte-specific
plasma protein with anti-inflammatory, antiatherogenic,
and antidiabetic properties (31), and it improves vascular
endothelial function via several mechanisms, including en-
hanced NO production by increased endothelial NO syn-
thase activity and suppressed superoxide generation in
endothelial cells through an NAD(P)H oxidase-linked
mechanism (32,33). In the present study, serum adiponectin
concentrations decreased in the amlodipine group, but not
in the telmisartan group, during follow-up.
Further, serum LDL-cholesterol levels were significantly
decreased in the telmisartan treatment group but not in the
amlodipine treatment group. Telmisartan effectively reduces
LDL-cholesterol levels by different mechanisms than statins
(34). Telmisartan may accelerate reverse cholesterol trans-
port from nonhepatic peripheral cells to the liver, thereby
lowering LDL cholesterol. Furthermore, telmisartan might
inhibit intestinal cholesterol absorption via its PPAR-gamma–
activating effect.
Thus, PPAR-gamma–mediated effects of telmisartan
might confer vascular protection through several mecha-
nisms after SES implantation.
Comparison between telmisartan and amlodipine in amelioration
of endothelial dysfunction after DES. Amlodipine improves
endothelial function and has antioxidant properties (35). In
the present study, however, telmisartan treatment induced
significantly stronger amelioration of endothelial dysfunc-
tion after DES implantation than amlodipine treatment did.
Consistent with our results, a recent randomized study
demonstrated that, compared with the calcium-channel
blocker amlodipine, telmisartan treatment improves endo-
thelial function (flow-mediated dilation) in peripheral ves-
sels in hypertensive patients (13).
Study limitations. The present study was a single-center
study with a small sample size. The lesions involved in
the study were limited to a single stenosis suitable for
treatment with 1 or 2 SES. In addition, the present study
focused on the first-generation DES (SES), although
second-generation DES are commonly used in currentpractice. Further studies are needed to examine whether
this study finding is applicable to other DES, especially
second-generation DES.
Furthermore, the results of the present study are only
preliminary; a larger number of subjects and a longer
follow-up for clinical outcomes are crucial to confirm the
efficacy of telmisartan treatment for hypertensive patients
with DES implantation.
Conclusions
In this group of hypertensive patients, compared with treat-
ment with a calcium-channel blocker, telmisartan treatment
significantly ameliorated endothelial dysfunction in terms of
ACh-induced vasoconstriction after DES implantation.
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